See also: Generic ActoPlus Met
ActoPlus Met XR is a brand name of metformin/pioglitazone, approved by the FDA in the following formulation(s):
ACTOPLUS MET XR (metformin hydrochloride; pioglitazone hydrochloride - tablet, extended release; oral)
Manufacturer: TAKEDA GLOBAL
Approval date: May 12, 2009
Strength(s): 1GM;EQ 15MG BASE, 1GM;EQ 30MG BASE [RLD]
Has a generic version of ActoPlus Met XR been approved?
No. There is currently no therapeutically equivalent version of ActoPlus Met XR available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of ActoPlus Met XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Pharmaceutical composition
Patent 5,965,584
Issued: October 12, 1999
Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
Assignee(s): Takeda Chemical Industries, Ltd.
Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.Patent expiration dates:
- June 19, 2016✓✓
- June 19, 2016
Controlled release oral tablet having a unitary core
Patent 6,099,859
Issued: August 8, 2000
Inventor(s): Cheng; Xiu Xiu & Chen; Chih-Ming & Jan; Steve & Chou; Joseph
Assignee(s): Andrx Pharmaceuticals, Inc.
A controlled release antihyperglycemic tablet that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane coating the core and at least one passageway in the membrane.Patent expiration dates:
- March 20, 2018✓
- March 20, 2018
Pharmaceutical composition
Patent 6,166,042
Issued: December 26, 2000
Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
Assignee(s): Takeda Chemical Industries, Ltd.
Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.Patent expiration dates:
- June 19, 2016✓
- June 19, 2016
Pharmaceutical composition
Patent 6,166,043
Issued: December 26, 2000
Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
Assignee(s): Takeda Chemical Industries, Ltd.
Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.Patent expiration dates:
- June 19, 2016✓
- June 19, 2016
Pharmaceutical composition
Patent 6,172,090
Issued: January 9, 2001
Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
Assignee(s): Takeda Chemical Industries, Ltd.
Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.Patent expiration dates:
- June 19, 2016✓
- June 19, 2016
Controlled release oral tablet having a unitary core
Patent 6,495,162
Issued: December 17, 2002
Inventor(s): Xiu Xiu; Cheng & Chih-Ming; Chen & Steve; Jan & Joseph; Chou
Assignee(s): Andrx Pharmaceuticals, Inc.
A controlled release antihyperglycemic tablet that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane coating the core and at least one passageway in the membrane.Patent expiration dates:
- March 20, 2018✓
- March 20, 2018
Methods for treating diabetes via administration of controlled release metformin
Patent 6,790,459
Issued: September 14, 2004
Inventor(s): Xiu Xiu; Cheng & Chih-Ming; Chen & Steve; Jan & Joseph; Chou
Assignee(s): Andrx Labs, LLC
A method for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at a 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.Patent expiration dates:
- March 17, 2021✓
- March 17, 2021
Controlled release metformin compositions
Patent 6,866,866
Issued: March 15, 2005
Inventor(s): Chen; Chih-Ming & Cheng; Xiu-Xiu & Jan; Steve & Chou; Joseph
Assignee(s): Andrx Labs, LLC
A composition for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.Patent expiration dates:
- March 17, 2021✓
- March 17, 2021
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Patent 7,785,627
Issued: August 31, 2010
Inventor(s): Kositprapa; Unchalee & Goldfarb; Robert I. & Cardinal; John & Nangia; Avinash
Assignee(s): Watson Pharmaceuticals, Inc.
A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.Patent expiration dates:
- July 31, 2026✓
- July 31, 2026
Controlled release metformin formulations
Patent 7,919,116
Issued: April 5, 2011
Inventor(s): Chen; Chih-Ming & Cheng; Xiu Xiu & Jan; Steve & Chou; Joseph
Assignee(s): Andrx Labs, LLC
Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration.Patent expiration dates:
- March 20, 2018✓
- March 20, 2018✓
- March 20, 2018
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Patent 7,959,946
Issued: June 14, 2011
Inventor(s): Kositprapa; Unchalee & Goldfarb; Robert I. & Cardinal; John R. & Nangia; Avinash
Assignee(s): Watson Pharmaceuticals, Inc.
A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.Patent expiration dates:
- July 31, 2026✓
- July 31, 2026
See also...
- Actoplus Met XR Extended-Release Tablets Consumer Information (Wolters Kluwer)
- Actoplus Met XR Consumer Information (Cerner Multum)
- Actoplus Met XR Advanced Consumer Information (Micromedex)
- Metformin Extended-Release/Pioglitazone Consumer Information (Wolters Kluwer)
- Metformin/Pioglitazone Consumer Information (Wolters Kluwer)
- Pioglitazone/Metformin Consumer Information (Wolters Kluwer)
- Pioglitazone/Metformin Extended-Release Tablets Consumer Information (Wolters Kluwer)
- Metformin and pioglitazone Consumer Information (Cerner Multum)
- Metformin and pioglitazone Advanced Consumer Information (Micromedex)
- Pioglitazone and metformin Advanced Consumer Information (Micromedex)
No comments:
Post a Comment